Viridian net loss widens to $127.12 million in Q2 FY26; SG&A expenses climb to $54.98 million - VRDN News | RalliesViridian net loss widens to $127.12 million in Q2 FY26; SG&A expenses climb to $54.98 million
V
VRDN• Second-quarter financial results
- Viridian Therapeutics posted a GAAP net loss of $127.12 million, widening from $100.74 million a year earlier.
- GAAP revenue rose to $284,000 from $75,000, driven by $233,000 of license revenue.
- R&D expense fell to $71.58 million from $86.63 million, while SG&A jumped to $54.98 million from $20.22 million on commercial build-out.
Cash position and business update
- Cash, cash equivalents, and marketable securities climbed to $981.53 million at June 30 from $762.2 million at March 31.
- Lumvoa won FDA approval for thyroid eye disease on June 26 and launched in the U.S.; elegrobart remains on track for BLA submission in Q1 2027.
BIVI
•
